A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)

Exclusion Criteria

• •1. Active central nervous system (CNS) leukemia or known CNS leukemia.
• •2. Immediately life-threatening, severe complications of leukemia.
• •3. Impaired cardiac function or clinically significant cardiac diseases.
• •4. Glucose-6-phosphate dehydrogenase (G6PD) deficiency.
• •5. Prior autologous hematopoietic stem cell transplant ≤ 3 months.
• •6. Prior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or reduced intensity conditioning ≤ 6 months.
• •7. Systemic immunosuppressive therapy post HSCT or with clinically significant graft-versus-host disease (GVHD).
• •8. Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives or 4 weeks whichever is shorter.
• •9. Major surgery ≤ 2 weeks and recovered from any clinically significant effects of recent surgery.
• •10. Pregnant or nursing females.
• •11. Known HIV infection.
• •12. Known chronic hepatitis B or C (HBV/HCV) infection.
• •13. Ongoing treatment with chronic, therapeutic dosing of anti-coagulants.
• •14. History of autoimmune hemolytic anemia or autoimmune thrombocytopenia.
• •15. History of concurrent second cancers requiring active, ongoing systemic treatment.
• •16. Subjects for whom potentially curative anticancer therapy is available.